Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Circulating Tumor Cell Counts in Patients With Localized Prostate Cancer Including Those Under Active Surveillance.

Choi SY, Lim B, Kyung YS, Kim Y, Kim BM, Jeon BH, Park JC, Sohn YW, Lee JH, Uh JH, Jang S, Kim CS.

In Vivo. 2019 Sep-Oct;33(5):1615-1620. doi: 10.21873/invivo.11645.

2.

Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer.

Benko G, Spajić B, Krušlin B, Tomas D.

Urol Oncol. 2013 May;31(4):468-74. doi: 10.1016/j.urolonc.2011.03.007. Epub 2011 Apr 21.

PMID:
21514185
3.

Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer.

Meyer CP, Pantel K, Tennstedt P, Stroelin P, Schlomm T, Heinzer H, Riethdorf S, Steuber T.

Urol Oncol. 2016 May;34(5):235.e11-6. doi: 10.1016/j.urolonc.2015.12.003. Epub 2016 Jan 12.

PMID:
26795608
4.
5.

Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy.

Onstenk W, Kraan J, Mostert B, Timmermans MM, Charehbili A, Smit VT, Kroep JR, Nortier JW, van de Ven S, Heijns JB, Kessels LW, van Laarhoven HW, Bos MM, van de Velde CJ, Gratama JW, Sieuwerts AM, Martens JW, Foekens JA, Sleijfer S.

Mol Cancer Ther. 2015 Mar;14(3):821-7. doi: 10.1158/1535-7163.MCT-14-0653. Epub 2014 Dec 31.

6.

Characterization of Urothelial Cancer Circulating Tumor Cells with a Novel Selection-Free Method.

Chalfin HJ, Kates M, van der Toom EE, Glavaris S, Verdone JE, Hahn NM, Pienta KJ, Bivalacqua TJ, Gorin MA.

Urology. 2018 May;115:82-86. doi: 10.1016/j.urology.2018.01.036. Epub 2018 Feb 9.

PMID:
29432873
7.

Nanoroughened adhesion-based capture of circulating tumor cells with heterogeneous expression and metastatic characteristics.

Chen W, Allen SG, Reka AK, Qian W, Han S, Zhao J, Bao L, Keshamouni VG, Merajver SD, Fu J.

BMC Cancer. 2016 Aug 8;16:614. doi: 10.1186/s12885-016-2638-x.

8.

Prostate extracellular vesicles in patient plasma as a liquid biopsy platform for prostate cancer using nanoscale flow cytometry.

Biggs CN, Siddiqui KM, Al-Zahrani AA, Pardhan S, Brett SI, Guo QQ, Yang J, Wolf P, Power NE, Durfee PN, MacMillan CD, Townson JL, Brinker JC, Fleshner NE, Izawa JI, Chambers AF, Chin JL, Leong HS.

Oncotarget. 2016 Feb 23;7(8):8839-49. doi: 10.18632/oncotarget.6983.

9.

EpCAMhigh and EpCAMlow circulating tumor cells in metastatic prostate and breast cancer patients.

de Wit S, Manicone M, Rossi E, Lampignano R, Yang L, Zill B, Rengel-Puertas A, Ouhlen M, Crespo M, Berghuis AMS, Andree KC, Vidotto R, Trapp EK, Tzschaschel M, Colomba E, Fowler G, Flohr P, Rescigno P, Fontes MS, Zamarchi R, Fehm T, Neubauer H, Rack B, Alunni-Fabbroni M, Farace F, De Bono J, IJzerman MJ, Terstappen LWMM.

Oncotarget. 2018 Nov 2;9(86):35705-35716. doi: 10.18632/oncotarget.26298. eCollection 2018 Nov 2.

10.

Improved ovarian cancer EMT-CTC isolation by immunomagnetic targeting of epithelial EpCAM and mesenchymal N-cadherin.

Po JW, Roohullah A, Lynch D, DeFazio A, Harrison M, Harnett PR, Kennedy C, de Souza P, Becker TM.

J Circ Biomark. 2018 Jun 24;7:1849454418782617. doi: 10.1177/1849454418782617. eCollection 2018 Jan-Dec.

11.

Epithelial cell adhesion molecule-positive circulating tumor cells as predictive biomarker in patients with prostate cancer.

Amato RJ, Melnikova V, Zhang Y, Liu W, Saxena S, Shah PK, Jensen BT, Torres KE, Davis DW.

Urology. 2013 Jun;81(6):1303-7. doi: 10.1016/j.urology.2012.10.041. Epub 2013 Apr 23.

PMID:
23622774
12.

Detection of live circulating tumor cells by a class of near-infrared heptamethine carbocyanine dyes in patients with localized and metastatic prostate cancer.

Shao C, Liao CP, Hu P, Chu CY, Zhang L, Bui MH, Ng CS, Josephson DY, Knudsen B, Tighiouart M, Kim HL, Zhau HE, Chung LW, Wang R, Posadas EM.

PLoS One. 2014 Feb 14;9(2):e88967. doi: 10.1371/journal.pone.0088967. eCollection 2014.

13.

Molecular detection of epithelial-mesenchymal transition markers in circulating tumor cells from pancreatic cancer patients: Potential role in clinical practice.

Zhao XH, Wang ZR, Chen CL, Di L, Bi ZF, Li ZH, Liu YM.

World J Gastroenterol. 2019 Jan 7;25(1):138-150. doi: 10.3748/wjg.v25.i1.138.

14.

Circulating tumor cells in patients with breast cancer: monitoring chemotherapy success.

Ušiaková Z, Mikulová V, Pintérová D, Brychta M, Valchář J, Kubecová M, Tesařová P, Bobek V, Kološtová K.

In Vivo. 2014 Jul-Aug;28(4):605-14.

PMID:
24982230
15.

Circulating tumor cells in patients with advanced urothelial carcinoma of the bladder: Association with tumor stage, lymph node metastases, FDG-PET findings, and survival.

Abrahamsson J, Aaltonen K, Engilbertsson H, Liedberg F, Patschan O, Rydén L, Sjödahl G, Gudjonsson S.

Urol Oncol. 2017 Oct;35(10):606.e9-606.e16. doi: 10.1016/j.urolonc.2017.05.021. Epub 2017 Jul 1.

PMID:
28676151
16.

Analogous detection of circulating tumor cells using the AccuCyte® -CyteFinder® system and ISET system in patients with locally advanced and metastatic prostate cancer.

van der Toom EE, Groot VP, Glavaris SA, Gemenetzis G, Chalfin HJ, Wood LD, Wolfgang CL, de la Rosette JJMCH, de Reijke TM, Pienta KJ.

Prostate. 2018 Mar;78(4):300-307. doi: 10.1002/pros.23474. Epub 2017 Dec 29.

PMID:
29285777
17.

Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the CellSearch(®) CTC test.

Adams DL, Stefansson S, Haudenschild C, Martin SS, Charpentier M, Chumsri S, Cristofanilli M, Tang CM, Alpaugh RK.

Cytometry A. 2015 Feb;87(2):137-44. doi: 10.1002/cyto.a.22613. Epub 2014 Dec 16.

18.

Association of preoperative EpCAM Circulating Tumor Cells and peripheral Treg cell levels with early recurrence of hepatocellular carcinoma following radical hepatic resection.

Zhou Y, Wang B, Wu J, Zhang C, Zhou Y, Yang X, Zhou J, Guo W, Fan J.

BMC Cancer. 2016 Jul 20;16:506. doi: 10.1186/s12885-016-2526-4.

19.

Clinical Relevance of a Candidate Stem Cell Marker, p75 Neurotrophin Receptor (p75NTR) Expression in Circulating Tumor Cells.

Okumura T, Yamaguchi T, Watanabe T, Nagata T, Shimada Y.

Adv Exp Med Biol. 2017;994:247-254. doi: 10.1007/978-3-319-55947-6_13. Review.

PMID:
28560678
20.

Circulating tumor cells in localized prostate cancer: isolation, cultivation in vitro and relationship to T-stage and Gleason score.

Kolostova K, Broul M, Schraml J, Cegan M, Matkowski R, Fiutowski M, Bobek V.

Anticancer Res. 2014 Jul;34(7):3641-6.

PMID:
24982381

Supplemental Content

Support Center